Bolder BioTechnology receives $600.

Bolder BioTechnology receives $600,000 NIH SBIR grant to review long-performing IL-11 analog in ARS Bolder BioTechnology, Inc . Today announced that it’s been awarded a Stage I SMALL COMPANY Innovation Analysis grant totaling $600,000 from the National Institute of Allergy and Infectious Illnesses of The National Institutes of Wellness . Advancement of radiological/nuclear countermeasures to take care of ARS is a higher priority research region for NIAID, stated George Cox, Ph.D., Business Principal and President Investigator for the grant.